Tender 2008 - letter to Medical Groups, DHB Hospital Pharmacies and interested parties

This is the text extract for Tender 2008 - letter to Medical Groups, DHB Hospital Pharmacies and interested parties - closes 5 November 2008, browse documents here.

24 September 2008 To: Medical Groups, DHB Hospital Pharmacies and Interested Parties

CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS ALL RESPONSES DUE BY 5PM, WEDNESDAY 5 NOVEMBER 2008

In accordance with PHARMAC’s objective of securing for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided, PHARMAC is consulting on the possibility of tendering for Sole Subsidised Supply and/or Hospital Supply Status of certain pharmaceuticals listed in Schedule One of this document. Attached to this letter is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are listed alphabetically by chemical, form and strength in therapeutic groups and have a ‘C’ and/or ‘H’ next to them to indicate whether they are being tendered for community and/or hospital supply. In general, the proposed Tender process would be similar to the 2007/08 Tender. A copy of the 2007/08 Invitation to Tender is available either on our website: www.pharmac.govt.nz, or by contacting PHARMAC. Comments Sought We seek comments on the approach outlined in the following pages, in particular the following: · · the proposed process and timetable; the actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and for hospital pharmaceuticals what the appropriate Discretionary Variance Limit for each pharmaceutical would be, where a 1% Discretionary Variance Limit is considered clinically unacceptable.

All comments, whether on the above described matters or not, received by 5 November 2008 will be considered by PHARMAC prior to finalisation of the 2008/09 Tender process and the list of pharmaceuticals to be tendered for Sole Subsidised Supply and/or Hospital Supply Status.

A232709 - qA12214

Background Since 1997 PHARMAC has been using the strategy of tendering for sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of off patent pharmaceuticals. It is proposed that the community Tender and hospital Tender processes continue to be run in unison, however the pharmaceutical list for community and hospital pharmacies may be different. Key Aspects of Awarding a Tender for Community Pharmaceuticals: · For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2012 for all awarded Tenders. The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer’s surcharge (that is the additional patient charge above that of the patient copayment), would become fully subsidised if a Tender was awarded. No other brand of the pharmaceutical could be listed (or subsidised) on the Pharmaceutical Schedule during the Tender period (subject to any Alternative Brand Access, as proposed). Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a Government subsidy.

Key Aspects of Awarding a Tender for the DHB Hospital Pharmaceuticals: · For the DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2012 for all awarded Tenders. No other brand of the pharmaceutical would be listed (or purchased) on Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.

The Process The Tender process is run annually; the proposed timelines for the 2008/09 Tender are as follows: Date

September/October 2008 5 November 2008 November 2008 A232709 - qA12214

Event

Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for all consultation to be received. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.

November/December 2008 Late December 2008 Late February 2009 From March 2009 30 June 2012

Consultation and Board decisions on Alternative Commercial Proposals to tendering from pharmaceutical suppliers. Issuing of the 2008/09 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2008/09 Tender. Terms after the End Date may apply.

Reference Pricing in the Community Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios in the community market including: 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup. 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider any clinical considerations associated with such scenarios. Contractual obligations for suppliers A copy of the draft contractual requirements which would form the terms of the contract with successful suppliers in the 2008/09 Tender is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50.

Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 15 December 2006 (2006/07 Tender) and the Invitation to Tender dated 21 December 2007 (2007/08 Tender) prior to issuing the 2008/09 Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in December 2008. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out

A232709 - qA12214

in Schedule One of this document. PHARMAC is currently seeking comments from suppliers about keeping any unresolved Tender Bid(s) open for acceptance. Access to Alternative Brands PHARMAC is continuing work to identify mechanisms that can reduce the impact on patients of brand changes. We will keep you informed as this work continues to progress. In the meantime, PHARMAC has undertaken a preliminary assessment to determine which products are appropriate for inclusion in this years’ tender. We welcome specific comments in relation to any implications of tendering items included in Schedule Two. Distribution of Consultation Documents Please note that this consultation letter has been widely distributed however should you consider that a particular person, group or agency should receive this and future Tender documents please feel free to contact PHARMAC (also available from our website). We also invite any person or group to contact PHARMAC should you wish to have a meeting to discuss this consultation document. Please direct any queries you may have to Yvonne Chen [DDI: (04) 916 7556] at PHARMAC for questions in relation to community supply, and Andrew Davies [DDI: (04) 916 7531] for questions in relation to hospital supply. Yours sincerely

Steffan Crausaz Manager, Funding and Procurement

A232709 - qA12214

Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Annex The pharmaceuticals have been listed in therapeutic groups according to the classification system used in the Pharmaceutical Schedule. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one.

Therapeutic Group Alimentary Tract and Metabolism Blood and Blood Forming Organs Cardiovascular System Dermatologicals Extemporaneously Compounded Preparations Genito-Urinary System Hormone Preparations – Systemic excluding contraceptives Infections – Agents for Systemic Use Musculo-Skeletal System Nervous System Oncology and Immunosuppressants Respiratory System and Allergies Sensory Organ Special Foods Page Numbers 7–8 8– 9 9 – 12 12 – 13 13 13 13 – 14 14 – 17 17 – 18 18 – 22 22 – 24 24 – 25 25 25 – 26

Information provided for each pharmaceutical For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information: · · · · the current ex-manufacturer subsidy per unit of measure as at 1 September 2008; number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2008; estimated annual community market value at current subsidies; and comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June 2008. These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals.

A232709 - qA12214

We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2008 by the relevant listed unit subsidy as at 1 September 2008. Patents A number of pharmaceuticals included in this list may still be on patent. Based on information available to PHARMAC, we believe these patents will expire by within the sole supply period. While PHARMAC has taken care in preparing the information contained in this table, it does not make any representation as to the accuracy of this information and accepts no liability in the event that the information is incorrect. Suppliers remain responsible for ensuring they do not infringe patents. Suppliers are responsible for their own independent assessment of the information and must decide for themselves whether or not to make an investment and on what terms.

Explanation of terms, symbols and abbreviations Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed. The following table explains the symbols used in the draft pharmaceutical list:

Symbol Underline C H PCT + * Explanation Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2009 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date. To be tendered for Sole Subsidised Supply (community pharmaceuticals). To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals). A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project. PHARMAC has been advised of the existence of a process patent. There is no fully funded product available for this line item (in relation to community supply).

A232709 - qA12214

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Units Cost Unit Subsidy DV Limit Comments

Alimentary Tract and Metabolism

Acarbose Tab 50 mg Tab 100 mg Amphotericin B Emulsion for infusion 5 mg per ml Liposomal Inj 50 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule

501,151 178,370

$122,504 $61,439

$0.2444 $0.3444

C H C H

1% 1%

Ascorbic Acid Inj 500 mg per 5 ml Tab 50 mg Tab 100 mg Tab 250 mg 1,163,211 $40,131 $0.0345 H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Atropine Sulphate Inj 400 mcg, 1 ml Inj 600 mcg, 1 ml Inj 1200 mcg, 1 ml Calcitriol Cap 0.25 mcg Cap 0.5 mcg Calcium Carbonate with Aminoacetic Acid Tab 400-420 mg with aminoacetic acid 180 mg 1,309,386 $39,282 $0.0300 C H 1%

Dose range of 400-420 mg elemental calcium per tablet required

C H 74,203 8,555 $38,586 $5,475 $0.5200 $0.6400 C H C H

1% 1% 1%

Not currently listed in the Pharmaceutical Schedule

2,655,022 374,927

$357,100 $93,544

$0.1345 $0.2495

C H C H

1% 1%

Calcium Gluconate Inj 10%, 10 ml Famotidine Tab 20 mg Tab 40 mg Glycopyrronium Inj 0.2 mg per ml, 1 ml Hydrocortisone Acetate Rectal foam 10 %, CFC-free Iodine Soln aqueous BP C

Not currently listed on the Pharmaceutical Schedule. A Special Authority or endorsement (for use during pregnancy and breastfeeding only) may be applied.

1,666

$3,565

$2.1400

C H

794,073 663,356

$25,728 $30,116

$0.0324 $0.0454

C C

246,692

$246,692

$1.0000

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Iodine Tab 150-200 mcg C

Not currently listed on the Pharmaceutical Schedule. A Special Authority or endorsement (for use during pregnancy and breastfeeding only) may be applied. A combination product would be considered; however it must contain 150 mcg -200 mcg of iodine.

Units

Cost

Unit Subsidy

DV Limit

Comments

Lansoprazole Cap 15 mg Cap 30 mg Mesalazine Enema 1 g per 100 ml Metformin Hydrochloride Tab 500 mg Tab 850 mg Miconazole Oral gel 20 mg per g Mucilaginous Laxatives Dry Dry-original flavour, regular texture only Sugar Free Pyridoxine Hydrochloride Tab 50 mg Thiamine Hydrochloride Inj 100 mg per ml, 2 ml C H 1%

Not currently listed on the Pharmaceutical Schedule

134,230 1,155,646

$20,618 $354,536

$0.1536 $0.3068

C H C H

1% 1%

44,152

$295,818

$6.7000

C H

65,764,349 14,906,417

$1,282,405 $477,005

$0.0195 $0.0320

C H C H

1% 1%

627,525

$140,409

$0.2238

52,686,510 7,344,541 1,074,077

$927,283 $129,264 $18,904

$0.0176 $0.0176 $0.0176

C H C H C H

1% 1% 1%

1,329,155

$46,866

$0.0353

Vitamin B Complex Tab, strong, BPC Vitamins Tab (BPC cap strength) 26,540,856 $392,805 $0.0148 C 2,181,455 $52,791 $0.0242 C

Blood and Blood Forming Organs

Aprotinin Inj 10,000 mcg per ml, 100 ml Inj 10,000 mcg per ml, 200 ml C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Atorvastatin Tab 10 mg Tab 20 mg Tab 40 mg 4,043,571 5,720,682 7,361,373 $543,052 $1,119,537 $1,997,140 $0.1343 $0.1957 $0.2713 * * *

+ + +

C C C

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Atorvastatin Tab 80 mg Units Cost Unit Subsidy DV Limit Comments

Not currently listed on the Pharmaceutical Schedule

Filgrastim Inj 0.3 mg per ml, 1 ml Folic Acid Tab 0.8 mg Tab 5 mg Gemfibrozil Cap 300 mg

Not currently listed on the Pharmaceutical Schedule

2,762,493 5,910,478

$45,581 $77,900

$0.0165 $0.0132

C C

Hydroxocobalamin Inj 1 mg per ml, 1 ml 229,445 $704,396 $3.0700 C H 1%

Currently two different subsidies, unit subsidy reflects the lower of the two

Magnesium Sulphate Inj 49.3%, 5 ml Nicotinic Acid Tab 25 mg Tab 50 mg Tab 100 mg Tab 500 mg Phenindione Tab 10 mg Tab 25 mg Tab 50 mg Potassium Chloride Tab long-acting 600 mg Sodium Bicarbonate Inj 8.4%, 50 ml Inj 8.4% 100 ml Inf 5%, 500 ml Tranexamic Acid Inj 100 mg per ml, 5 ml Urokinase Inj 10,000 iu Inj 500,000 iu H H 1% 1% H 1% 1,927 2,203 $38,444 $45,162 $19.9500 $20.5000 C H C H H 1% 1% 1% 11,543,083 $300,120 $0.0260 C H 1% H H H 1% 1% 1% 725,913 $127,761 $0.1760 1,158,927 $58,873 $0.0508 C C C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Cardiovascular System

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Aprotinin Inj 10,000,000 iu per ml, 50 ml Arginine Inj 5%, 500 ml Atenolol Tab 50 mg Tab 100 mg Celiprolol Tab 200 mg Clonidine Inj 150 mcg per ml, 1 ml Tab 25 mcg Tab 150 mcg TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day Dobutamine Inj 12.5 mg per ml, 20 ml Enalapril Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 20 mg Enalapril With Hydrochlorothiazide Tab 20 mg with hydrochlorothiazide 12.5 mg Felodipine Tab long-acting 2.5 mg Tab long-acting 5 mg Tab long-acting 10 mg Flecainide Acetate Cap long-acting 100 mg Cap long-acting 200 mg Inj 10 mg per ml, 15 ml Tab 50 mg Tab 100 mg Frusemide Tab 40 mg 36,001,746 $414,020 $0.0115 C H 1% 648,558 522,648 18 249,598 239,890 $925,687 $1,317,596 $176 $178,138 $302,381 $1.4273 $2.5210 $9.8040 $0.7137 $1.2605 C H C H C H C H C H 1% 1% 1% 1% 1% 8,177,612 14,589,483 10,114,257 $2,829,454 $2,674,739 $2,697,135 $0.3460 $0.1833 $0.2667 C H C H C H 1% 1% 1% 426,921 $47,246 $0.1107 * C H 1% 4,518,231 3,869,420 3,152,044 $109,944 $118,662 $128,884 $0.0243 $0.0307 $0.0409 C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

C H

9,451,084 3,407,916

$122,864 $77,019

$0.0130 $0.0226

C H C H

1% 1%

6,179,652

$652,571

$0.1056

C H

8,495 2,622,929 507,228 36,752 12,937 9,885

$23,786 $459,799 $153,842 $195,613 $99,583 $96,626

$2.8000 $0.1753 $0.3033 $5.3225 $7.6975 $9.7750

C H C H C H C H C H C H

1% 1% 1% 1% 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Frusemide Tab 500 mg Glyceryl Trinitrate Inj 1 mg per ml, 5 ml Inj 1 mg per ml, 50 ml Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Hydralazine Inj 20 mg per ml, 1 ml Hydrochlorothiazide Tab 12.5 mg Tab 25 mg C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

220,562

$26,467

$0.1200

C H

H H H H

1% 1% 1% 1%

463

$2,398

$5.1800

C H

Lisinopril Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 20 mg Lisinopril with Hydrochlorothiazide Tab 20 mg with hydrochlorothiazane 12.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

C H 606,533 575,487 717,210 $56,205 $60,618 $93,476 $0.0927 $0.1053 $0.1303 C H C H C H

1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Losartan Tab 12.5 mg Tab 25 mg 1,423,394 105 $825,569 $76 $0.5800 $0.7254 C H C H 1% 1%

This was recently listed on the Pharmaceutical Schedule

Tab 50 mg Tab 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Tab 100 mg with hydrochlorothiazide 25 mg

2,186,442 165,131 569,215

$1,683,560 $194,855 $569,215

$0.7700 $1.1800 $1.0000

C H C H C H C H

1% 1% 1% 1%

Not currently listed in the Pharmaceutical Schedule

Metaraminol Tartrate Inj 10 mg per ml, 1 ml Milrinone Inj 1 mg per ml, 10 ml Noradrenaline Acid Tartrate Inj 0.1 mg per ml, 100 ml bag Phenoxybenzamine Inj 100 mg per 2 ml H 1% H 1% H 1% H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Pindolol Tab 5 mg Tab 10 mg Tab 15 mg Propranolol Cap long-acting 160 mg Tab 10 mg Tab 40 mg Timolol maleate Tab 10 mg 193,209 $20,384 $0.1055 C 657,431 1,986,827 2,286,674 $111,106 $70,532 $106,330 $0.1690 $0.0355 $0.0465 C H C H C H 1% 1% 1% 311,631 318,076 155,255 $14,023 $26,559 $18,631 $0.0450 $0.0835 $0.1200 C H C H C H 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments

Dermatologicals

Acitretin Cap 10 mg Cap 25 mg Betamethasone Valerate Scalp app 0.1% Calamine Crm, aqueous, BP Lotn, BP Chlorhexidine Crm 1% obstetric Chlorhexidine Gluconate Handrub 0.5% - 1% with ethanol 70% 2,168,302 $23,418 $0.0108 C

Chlorhexidine strengths from 0.5% to 1% would be considered

286,675 87,123

$271,625 $177,470

$0.9475 $2.0370

C C

3,105,621

$163,045

$0.0525

C H

176,113 4,284,946

$5,319 $41,650

$0.0302 $0.0097

C C

Ciclopiroxolamine Crm 1% Nail soln 8% Soln 1% Clobetasol Propionate Crm 0.05% Oint 0.05% Scalp app 0.05% Hydrocortisone Crm 1% (pack size 15 g or less) 17,399,193 $424,540 $0.0244 C H 1%

Volume is aggregated for all pack sizes of hydrocortisone cream Volume is aggregated for all pack sizes of hydrocortisone cream

36,090 58,828 35,599

$1,805 $635,510 $7,761

$0.0500 $10.8029 $0.2180

* * *

C C C

2,450,584 2,357,714 595,476

$191,962 $125,745 $63,517

$0.0783 $0.0533 $0.1067

C H C H C H

1% 1% 1%

Crm 1% (pack size greater than 15 g and 100 g or less)

17,399,193

$424,540

$0.0244

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Hydrocortisone with Miconazole Crm 1% with miconazole nitrate 2% Isotretinoin Cap 10 mg 1,079,577 $388,648 $0.3600 C H 1%

Information on appropriate use should be available on a website Information on appropriate use should be available on a website. Information on appropriate use should be available on a website. Not currently listed on the Pharmaceutical Schedule.

Units

Cost

Unit Subsidy

DV Limit

Comments

3,308,557

$485,365

$0.1467

Cap 20 mg

1,942,915

$922,885

$0.4750

C H

Cap 40 mg

C H

Mupirocin Nasal oint 2% Paraffin White soft or yellow soft (pack size 30 g or less) H 1% H 1%

Extemporaneously Compounded Preparations and Galenicals

Sodium Bicarbonate Powder BP 168,898 $3,310 $0.0196 C H 1%

Genito-Urinary System

Alprostadil Inj 0.5 mg per ml, 1 ml Ergometrine Maleate Inj 500 mcg per ml, 1 ml Norethisterone Tab 350 mcg Oxytocin Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Pregnancy Tests - HCG Urine Urine diagnostic test 361,483 $274,727 $0.7600 C H 1% 965 4,462 2,783 $1,042 $6,068 $5,121 $1.0800 $1.3600 $1.8400 C H C H C H 1% 1% 1% 9,474,169 $806,432 $0.0851 C 2,106 $4,886 $2.3200 C H 1% H 1%

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Clomiphene Citrate Tab 50 mg Cyproterone Acetate Tab 50 mg Tab 100 mg 996,277 $468,250 $0.4700 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

44,271

$22,136

$0.5000

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Danazol Cap 100 mg Cap 200 mg Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Ethinyloestradiol Tab 10 mcg Etidronate Disodium Tab 200 mg Hydrocortisone Tab 5 mg Tab 20 mg Methylprednisolone Inj 500 mg Inj 1 g Tab 4 mg Tab 100 mg Methylprednisolone Sodium Succinate Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Oestrogens Conjugated, equine tab 300 mcg Testosterone Transdermal patch 2.5 mg per day 104,975 $139,963 $1.3333 C H 1% 1,203,803 $129,409 $0.1075 * C 1,204 834 $7,291 $13,764 $6.0560 $16.5036 C H C H 1% 1% 308 290 26,618 17,765 $5,067 $12,345 $12,928 $147,911 $16.4500 $42.5700 $0.4857 $8.3260 C H C H C H C H 1% 1% 1% 1% 2,440,393 141,826 $194,011 $28,294 $0.0795 $0.1995 C H C H 1% 1% 1,719,628 $653,459 $0.3800 C H 1% 305,869 $53,833 $0.1760 C 19,530 72,426 $83,979 $449,041 $4.3000 $6.2000 C H C H 1% 1% 12,211 30,018 $10,175 $17,011 $0.8333 $0.5667 C H C H 1% 1% Units Cost Unit Subsidy DV Limit Comments

Infections - Agents for Systemic Use

Abacavir Sulphate Oral liq 20 mg per ml Tab 300 mg Abacavir sulphate with lamivudine Tab 600 mg with lamivudine 300 mg Aciclovir Inj 250 mg Inj 500 mg Inj 1,000 mg H H H 1% 1% 1% 36,458 $765,618 $21.0000 26,298 72,537 $10,958 $553,699 $0.4167 $7.6333 C H C H 1% 1%

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Aciclovir Tab 200 mg C H 1%

Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule.

Units

Cost

Unit Subsidy

DV Limit

Comments

Tab 400 mg

C H

Tab 800 mg

C H

Tab dispersible 200 mg Tab dispersible 400 mg Tab dispersible 800 mg Amikacin Inj 5 mg per ml, 5 ml Inj 250 mg per ml, 2 ml Amoxycillin Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Sachets 3 g

815,115 3,046,791 497,147

$64,557 $361,349 $104,848

$0.0792 $0.1186 $0.2109

C H C H C H

1% 1% 1%

H H

1% 1%

29,891,936 22,765,928

$298,919 $289,127

$0.0100 $0.0127

C H C H C H

1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Amoxycillin Clavulanate Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Azithromycin Tab 500 mg Caspofungin Inj 50 mg Inj 70 mg Cefazolin Sodium Liq C H 1%

Not currently listed on the Pharmaceutical Schedule

12,012,266 15,612,478

$330,337 $741,593

$0.0275 $0.0475

C H C H

1% 1%

93,956

$465,082

$4.9500

C H

H H

1% 1%

Cephradine Liq C H 1%

Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Chloroquine Oral liq Tab 200 mg - 250 mg C C

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Dicloxacillin Inj 500 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Erythromycin Ethyl Succinate Tab 400 mg Flucloxacillin Sodium Cap 250 mg Cap 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Fluconazole Inj 2 mg per ml, 50 ml Gentamicin Sulphate Inj 40 mg per ml, 2 ml Lamivudine Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 100 mg Tab 150 mg Nevirapine Oral suspension 10 mg per ml Oral suspension 50 mg per 5 ml Tab 200 mg Pyrantel Embonate Oral suspension Tab $0.2950 * C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule A variety of oral solid dose forms would be considered. Note this product has been discontinued.

4,664,291

$883,883

$0.1895

C H

1,289,694 7,610,215 4,295,279 5,616,300

$95,437 $881,263 $88,053 $152,763

$0.0740 $0.1158 $0.0205 $0.0272

C H C H C H C H

1% 1% 1% 1%

6,288

$2,867

$0.4560

C H

240 83,825 299,522 80,464

$90 $34,930 $1,529,689 $411,976

$0.3750 $0.4167 $5.1071 $5.1200

C C C C

43,764

$24,534

$0.5606

C H C H

1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

123,184

$656,571

$5.3300

C H

Roxithromycin Tab 150 mg Tab 300 mg Streptomycin Inj 1 g H 1% 1,711,147 700,273 $325,118 $252,098 $0.1900 $0.3600 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Tetracycline Hydrochloride Cap 250 mg C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Ticarcillin Inj 1 g Inj 3 g H H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Zidovudine (AZT) with Lamivudine Tab 300 mg with lamivudine 150 mg 363,685 $4,044,177 $11.1200 C

Musculo-Skeletal System

Baclofen Inj 10 mg Oral liq 5 mg per 5 ml Tab 10 mg Tab 20 mg C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceuticcal Schedule Not currently listed on the Pharmaceutical Schedule

Dantrolene Sodium Cap 25 mg Cap 50 mg Inj 1 mg per ml, 20 ml Diclofenac Sodium Cap long-acting 100 mg Tab 50 mg dispersible Tab EC 25 mg Tab EC 50 mg Tab long-acting 75 mg Tab long-acting 100 mg Leflunomide Tab 10 mg Tab 20 mg Tab 100 mg Naproxen Tab 250 mg Tab 500 mg Quinine Sulphate Tab 200 mg Tab 300 mg 1,894,387 3,544,411 $120,862 $246,337 $0.0638 $0.0695 C H C H 1% 1% 1,138,443 2,585,347 $47,815 $185,628 $0.0420 $0.0718 C H C H 1% 1% 163,670 388,518 25 $432,471 $1,406,435 $454 $2.6423 $3.6200 $18.1467 C H C H C H 1% 1% 1% 813,172 498,946 3,827,691 21,240,802 4,444,439 $60,988 $17,513 $198,121 $967,731 $305,066 $0.0750 $0.0351 $0.0518 $0.0456 $0.0686 C H C H C H C H C H C H 1% 1% 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

130,888 53,732

$43,141 $27,779

$0.3296 $0.5170

C H C H H

1% 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Raloxifene Tab 60 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to an endorsement or Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

Rasburicase Inj 1.5 mg H 1%

Nervous System

Apomorphine Hydrochloride Inj 10 mg per ml, 1 ml Atracurium Besylate Inj 10 mg per ml, 2.5 ml Inj 10 mg per ml, 5 ml Bupivacaine hydrochloride Inf 0.125%, 100 ml Inf 0.125%, 200 ml Inf 0.25%, 100 ml Inj 0.25%, 20 ml Inj 0.375%, 20 ml Inj 0.5%, 4 ml theatre pack Inj 0.5%, 10 ml Inj 0.5%, 10 ml Theatre pack Inj 0.5%, 20 ml Inj 0.5%, 20 ml Theatre pack Bupivacaine Hydrochloride with Adrenaline Inj 0.25% with 1:400,000 of adrenaline, 10 ml Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack Inj 0.25% with 1:400,000 of adrenaline, 20 ml Inj 0.25% with 1:400,000 of adrenaline, 20 ml theatre pack Inj 0.5% with 1:200,000 of adrenaline, 10 ml Inj 0.5% with 1:200,000 of adrenaline, 10 ml theatre pack Inj 0.5% with 1:200,000 of adrenaline, 20 ml Inj 0.5% with 1:200,000 of adrenaline, 20 ml theatre pack Cocaine Soln 4%, 2 ml BP H 1% H H H H H H H H 1% 1% 1% 1% 1% 1% 1% 1% H H H H H H H H H H 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% H H 1% 1% 8,036 $81,051 $10.0860 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Cyclizine Hydrochloride Tab 50 mg Cyclizine Lactate Inj 50 mg per ml, 1 ml Diazepam Rectal tubes 5 mg Rectal tubes 10 mg Dopamine Inj 40 mg per ml, 5 ml Entacapone Tab 200 mg Ephedrine Sulphate Inj 30 mg per ml, 1 ml Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg Fentanyl Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 5 ml Inj 50 mcg per ml, 10 ml Inj 50 mcg per ml, 20 ml C H C H C H C H 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

677,078

$134,739

$0.1990

C H

56,899

$170,128

$2.9900

C H

11,015 15,928

$61,309 $246,151

$5.5660 $15.4540

C H C H

1% 1%

391,751

$505,359

$1.2900

C H

H PCT 1%

462,764

$143,457

$0.3100

C H

Gabapentin Cap 100 mg 895,270 $118,713 $0.1326 C H 5%

Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two.

Cap 300 mg

6,568,959

$2,613,789

$0.3979

C H

Cap 400 mg

814,273

$431,646

$0.5301

C H

Tab 600 mg

43,134

$34,417

$0.7979

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Imipramine Hydrochloride Tab 10 mg Tab 25 mg Ketamine Inj 100 mg per ml, 2 ml Levodopa with Benserazide Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Tab dispersible 50 mg with benserazide 12.5 mg Lignocaine Gel 2% Lorazepam Tab 1 mg Tab 2.5 mg Maprotiline Hydrochloride Tab 25 mg Tab 75 mg Methadone Hydrochloride Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Methylphenidate Hydrochloride Tab immediate-release 5 mg Tab immediate-release 20 mg Tab immediate-release 10 mg Tab sustained-release 20 mg 102,380 34,071 2,350,074 2,445,000 $10,924 $8,916 $336,061 $892,425 $0.1067 $0.2617 $0.1430 $0.3650 C H C H C H C H 1% 1% 1% 1%

Excludes long-acting or extended-release products

Units

Cost

Unit Subsidy

DV Limit

Comments

480,347 1,637,443

$84,541 $179,464

$0.1760 $0.1096

C H C H

1% 1%

1,017,949 1,218,285 654,911 153,844 580,338

$81,436 $152,286 $111,335 $38,461 $58,034

$0.0800 $0.1250 $0.1700 $0.2500 $0.1000

C H C H C H C H C H

1% 1% 1% 1% 1%

4,401,220 256,674

$110,559 $10,575

$0.0251 $0.0412

C H C H

1% 1%

92,569 16,952

$23,198 $11,871

$0.2506 $0.7003

C H C H

1% 1%

2,398,374 20,903,093 2,995,585

$78,547 $681,441 $142,290

$0.0328 $0.0326 $0.0475

C H C H C H

1% 1% 1%

Metoclopramide Hydrochloride with Paracetamol Tab 5 mg with paracetamol 500 mg Midazolam Inj 1 mg per ml, 5 ml Inj 5 mg per ml, 3 ml Moclobemide Tab 150 mg Tab 300 mg 1,491,347 356,795 $147,494 $93,159 $0.0989 $0.2611 C H C H 1% 1% H H 1% 1% 1,304,831 $70,670 $0.0542 C

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Morphine Hydrochloride Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Morphine Sulphate Cap long-acting 10 mg Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab immediate release 10 mg Tab immediate release 20 mg Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Oxycodone Hydrochloride Cap 5 mg Cap 10 mg Cap 20 mg Tab controlled-release 5 mg Tab controlled-release 10 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 80 mg Pancuronium bromide Inj 2 mg per ml, 2 ml Paracetamol Suppos 125 mg Suppos 250 mg Tab modified-release 665 mg 69,308 62,963 $22,560 $39,415 $0.3255 $0.6260 C H C H C 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

5,435,380 714,066 1,004,181 585,791

$219,046 $30,562 $48,251 $36,788

$0.0403 $0.0428 $0.0481 $0.0628

C H C H C H C H

1% 1% 1% 1%

2,944,101 1,014,236 407,958 299,552 22,986 11,669 1,289,061 659,111 772,937 388,234 185,167 253,839

$529,938 $267,758 $293,730 $235,148 $23,768 $10,969 $340,312 $336,147 $139,129 $139,764 $133,320 $215,763

$0.1800 $0.2640 $0.7200 $0.7850 $1.0340 $0.9400 $0.2640 $0.5100 $0.1800 $0.3600 $0.7200 $0.8500

C H C H C H C H C H C H C H C H C H C H C H C H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

23,383 1,793

$94,467 $24,159

$4.0400 $13.4740

C H C H

1% 1%

512,539 346,876 233,842 345,357 709,346 524,147 173,489 112,353

$72,524 $96,778 $114,232 $129,682 $395,106 $496,105 $288,772 $325,992

$0.1415 $0.2790 $0.4885 $0.3755 $0.5570 $0.9465 $1.6645 $2.9015

C H C H C H C H C H C H C H C H

1% 1% 1% 1% 1% 1% 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Pethidine Hydrochloride Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 1.5 ml Inj 50 mg per ml, 2 ml Rocuronium Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 10 ml Selegiline Hydrochloride Tab 5 mg Tetrabenazine Tab 25 mg Tropisetron Cap 5 mg Inj 1 mg per ml, 2 ml 8,623 $133,501 $15.4820 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

33,594 201 71,687

$25,196 $175 $59,930

$0.7500 $0.8700 $0.8360

C H C H C H

1% 1% 1%

H H

1% 1%

179,760

$28,869

$0.1606

111,640

$242,219

$2.1696

Vecuronium Inj 4 mg Inj 10 mg Zuclopenthixol Hydrochloride Tab 2 mg Tab 10 mg Tab 25 mg Tab 40 mg C H C H C H C H 1% 1% 1% 1%

H H

1% 1%

Oncology Agents and Immunosuppressants

Amsacrine Inj 50 mg per 1 ml Bleomycin sulphate Inj 15,000 iu Capecitabine Tab 150 mg Tab 500 mg Carboplatin Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 10 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml H PCT 1% H PCT 1% H PCT 1% H PCT 1% 613,071 117,595 $3,601,792 $225,394 $5.8750 $1.9167 C H C H 1% 1% H PCT 1% H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Carboplatin Inj 10 mg per ml, 100 ml Carmustine Inj 100 mg, 3 ml Cyclosporin Inf 50 mg per ml, 5 ml Dacarbazine Inj 200 mg Daclizumab Inj 25 mg per 5 ml Doxorubicin Inj 10 mg Inj 20 mg Inj 50 mg Inj 100 mg Inj 200 mg Epirubicin Inj 1 mg per ml, 5 ml Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Inj 2 mg per ml, 25 ml Inj 2 mg per ml, 50 ml Inj 2 mg per ml, 100 ml Etoposide Cap 50 mg Cap 100 mg Inj 20 mg per ml, 20 ml Inj 20 mg per ml, 50 ml Idarubicin hydrochloride Cap 5 mg Cap 10 mg Inj 5 mg Inj 10 mg Irinotecan Inj 20 mg per ml, 2 ml Inj 20 mg per ml, 5 ml H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 6,196 1,059 $105,558 $36,083 $17.0365 $34.0730 C H PCT 1% C H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H 1% H PCT 1% H 1% H PCT 1% H PCT 1% Units Cost Unit Subsidy DV Limit Comments

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Letrozole Tab 2.5 mg Methotrexate Tab 2.5 mg Tab 10 mg Mycophenolate Mofetil Cap 250 mg Inj 500 mg Powder for oral liq 1 g per 5 ml Tab 500 mg Oxaliplatin Inj 50 mg Inj 100 mg Vincristine Sulphate Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Vinorelbine Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 9,177 446,759 $15,851 $1,846,544 $1.7273 $4.1332 255,891 $528,824 $2.0666 C H H C H C H 1% 1% 1% 1% 1,816,012 254,883 $351,096 $208,647 $0.1933 $0.8186 C H PCT 1% C H PCT 1% 403,568 $1,970,219 $4.8820 C H 1% Units Cost Unit Subsidy DV Limit Comments

Respiratory System and Allergies

Beclomethasone Dipropionate Metered aqueous nasal spray, 50 mcg per dose 11,712,396 $137,621 $541,875 $0.0118 $0.0123 C H C H 1% 1%

Metered aqueous nasal spray, 100 mcg per dose 44,054,856 Beractant Inj 25 mg per ml, 8 ml Budesonide Metered aqueous nasal spray, 50 mcg per dose 5,253,314

$61,726 $388,008

$0.0118 $0.0131

* *

C H C H H H

1% 1% 1% 1%

Metered aqueous nasal spray, 100 mcg per dose 29,732,447 Nebuliser soln, 500 mcg per ml, 2 ml Nebuliser soln, 1 mg per ml, 2 ml Chlorpheniramine Maleate Cap long-acting 12 mg

C H

Not currently subsidised on the Pharmaceutical Schedule

Salbutamol Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml 441,581 1,052,618 $81,692 $202,629 $0.1850 $0.1925 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Salbutamol with Ipratropium Bromide Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Sodium Cromoglycate Nasal spray, 4% 49,813 $30,567 $0.6136 C 1,256,489 $332,970 $0.2650 C H 1% Units Cost Unit Subsidy DV Limit Comments

Sensory Organs

Acetylcholine Inj 10 mg per ml, 2 ml Betaxolol Hydrochloride Eye drops 0.25% Eye drops 0.5% Bimatoprost Eye Drops 0.03% Chloramphenicol Eye drops 0.5% 1,671,053 $233,947 $0.1400 C H 1%

Single dose presentation would not be a DV Pharmaceutical

65,418 9,179

$154,386 $13,769

$2.3600 $1.5000

C C

115,766

$752,479

$6.5000

Eye oint 1% Dorzolamide Hydrochloride Eye drops 2% Dorzolamide hydrochloride with timolol maleate Eye drops 2% with timolol maleate 0.5% Fluorometholone Eye drops 0.1% Sodium Cromoglycate Eye drops 2% Sodium Hyaluronate Inj 3% with 4% chondroitin sulphate, 0.35 ml Inj 3% with 4% chondroitin sulphate, 0.5 ml Ophthalmic inj 14 mg per ml Ophthalmic soln 10 mg per ml Sodium Hyaluronidate Inj 14 mg per ml Travoprost Eye drops 0.004%

451,236

$279,766

$0.6200

C H

27,856

$54,431

$1.9540

323,288

$1,196,166

$3.7000

C H

64,020

$55,057

$0.8600

C H

442,865

$174,932

$0.3950

H H H H

1% 1% 1% 1%

94,418

$736,460

$7.8000

Triamcinolone acetonide with gramicidin, neomycin and nystatin Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g 176,287 $78,742 $0.4467 C H 1%

Special Foods

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Oral Feed 1.5 KCal per ml Liq 774,764,134 $4,338,679 $0.0056 * C H 1%

Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the Pharmaceutical Schedule. Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the Pharmaceutical Schedule.

Units

Cost

Unit Subsidy

DV Limit

Comments

Liq with fibre

73,903,400

$413,859

$0.0056

C H

Metadata

Title

Tender 2008 - letter to Medical Groups, DHB Hospital Pharmacies and interested parties - closes 5 November 2008

Abstract

24 September 2008 To: Medical Groups, DHB Hospital Pharmacies and Interested Parties CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS ALL RESPONSES DUE BY 5PM, WEDNESDAY 5 NOVEMBER 2008 In accordance with PHARMAC’s objective of securing for eligible people in need of…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.